Drug Database
TI

timolol (timolol, Merck / Timoptol)

✓ Approved

Teva Pharmaceutical Industries Ltd. · ADRB1 · 小分子

什么是 timolol?

timolol 是一种小分子,由Teva Pharmaceutical Industries Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Others。

药物档案

商品名timolol, Merck, Timoptol
公司Teva Pharmaceutical Industries Ltd.
药物类别小分子
分子靶点ADRB1, ADRB2
给药途径Others
状态Approved

作用机制

分子靶点

timolol 作用于 2 个分子靶点:

ADRB1adrenoceptor beta 1 (B1AR, RHR)
ADRB2adrenoceptor beta 2 (B2AR, ADRBR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

timolol 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Eye disordersGlaucoma✓ Approved

相关研究文献

PubMedExpert opinion on drug safety2026-11-18

Ocular hyperemia with netarsudil/latanoprost fixed combination in glaucoma: an exploratory association analysis of tolerability outcomes by prior topical therapy and baseline ocular hyperemia.

Holló Gábor G

This post hoc analysis of MERCURY-3 evaluates factors associated with baseline ocular hyperemia and tolerability outcomes with netarsudil/latanoprost fixed combination (NET/LAT). MERCURY-3 was a prospective, randomized, double-masked, multicenter, Phase 3, European trial. Adults with open-angle glaucoma or ocular hypertension inadequately controlled on topical therapy were randomized to once-daily NET/LAT (n = 218) or bimatoprost/timolol fixed combination (BIM/TIM; n = 212) for 6 months. Patients were stratified by baseline ocular hyperemia status (none vs any grade) and associations with prior treatment, adverse events (AEs), and hyperemia evolution evaluated. In the NET/LAT arm, prior combination therapy was associated with a greater prevalence of baseline ocular hyperemia than prior monotherapy (distribution: p = 0.003). Patients with baseline hyperemia experienced higher rates of AEs (85% vs 63%), ocular treatment-related AEs (74% vs 39%), and conjunctival hyperemia (45% vs 26%) during treatment. Ocular hyperemia remained predominantly mild throughout follow-up, with a more stable severity trajectory linked to prior monotherapy compared with prior combination therapy. No comparable associations were observed with BIM/TIM. Prior treatment complexity and baseline ocular hyperemia status are associated with tolerability outcomes during NET/LAT therapy. These exploratory findings suggest that earlier step-up after monotherapy could be associated with more favorable tolerability. CT.gov identifier: NCT03284853.

PMID 43046532
阅读全文 →
PubMedInternational medical case reports journal2026-11-17

Management of Ahmed Glaucoma Valve Plate Exposure by Plate Removal and Tube Retention: A Case Report.

Alhemyari Mohammed S MS, Al-Hamdi Ibrahim Mohammed IM, Alhemyari Khalid K, Bamashmus Mahfouth A MA

Ahmed glaucoma valve (AGV) implantation is an established option for refractory glaucoma, including neovascular glaucoma (NVG). Exposure of glaucoma drainage device hardware is a serious complication because it increases the risk of infection and may require surgical repair or explantation. A 66-year-old man with diabetes, hypertension, and NVG secondary to diabetic retinopathy developed AGV plate exposure in the right eye two months after implantation. The exposed plate was removed while the tube was retained. The distal open end of the retained tube was positioned subconjunctivally approximately 8 mm posterior to the limbus beneath conjunctival/Tenon tissue. The tube was fixed to the sclera with 10-0 nylon, temporarily ligated with 7-0 Vicryl, and three fenestrations were created proximal to the ligature. Two weeks later, conjunctival wound dehiscence with tube exposure occurred and was repaired with an approximately 4 × 2 mm preserved scleral patch graft. At eight months after the final repair, the eye was quiet, the tube remained covered, and IOP was 14 mmHg while the patient was using dorzolamide-timolol. Tube function was not objectively confirmed. This case suggests that removal of an exposed Ahmed glaucoma valve (AGV) plate with retention of the tube may preserve a potential aqueous drainage pathway. However, subsequent conjunctival wound dehiscence and tube exposure required repair with a preserved scleral patch graft, highlighting the importance of adequate tube coverage, particularly in eyes with compromised conjunctiva. Following repair, tube coverage remained intact and intraocular pressure remained stable during eight months of follow-up, although the independent contribution of the retained tube to IOP control could not be confirmed. Longer follow-up and additional cases are needed to establish the efficacy and safety of this individualized approach.

PMID 43041822
阅读全文 →
PubMedJournal of ophthalmic & vision research2026-11-11

Unilateral Angle Closure as the Initial Presentation of Multiple Myeloma Metastasis.

Nguyen Thao Huong TH, Pham Truong Dang Minh TDM, Trang Thanh Nghiep TN, Ly Ngoc Phuong Vy NPV et al.

Ocular manifestations of multiple myeloma (MM) are rare but may affect all tissues of the eye. This report describes a patient with recurrent MM initially presenting with ocular hypertension due to angle closure, revealing extensive ocular, orbital, and systemic metastatic disease. A 54-year-old female patient with previously treated MM presented with left eye pain, blurred vision, and an intraocular pressure of 38 mmHg. Examination revealed proptosis, restricted upward gaze, conjunctival injection with two salmon-patch lesions, and complete angle closure. Further findings included multiple ciliary body cysts, a massive choroidal mass, and retinal/choroidal detachments. She had pancytopenia. Magnetic resonance imaging confirmed recurrent MM with superior rectus muscle and spine infiltrations, and a large prevertebral lymph node mass. The patient responded well to antiglaucoma medications and was referred to her oncologist. MM can involve various ophthalmic structures. Patients with MM require regular examinations for early detection of ocular metastasis.

PMID 43011673
阅读全文 →
PubMedCirugia pediatrica : organo oficial de la Sociedad Espanola de Cirugia Pediatrica2026-11-06

Topical timolol in the treatment of pediatric pyogenic granuloma: A 23-case series.

Sánchez Pulido L J LJ, Vega Mata N N, Enríquez Zarabozo E M EM, Granell Suárez C C et al.

Pyogenic granuloma (PG) is a common benign vascular lesion in pediatric patients, characterized by rapid growth and a tendency to bleed. Surgical excision allows immediate resolution and histological confirmation, with low recurrence when including the base of the lesion, although it may require anesthesia and leave a scar. Topical timolol has emerged as a conservative alternative in selected patients. To evaluate the efficacy and safety of topical timolol 0.5% in the treatment of PG in pediatric patients. Retrospective case series of 23 pediatric patients (4 months-13 years) diagnosed with PG and treated between 2018 and 2024 with a 0.5% timolol formulation applied topically over the lesion as an off-label use. Demographic and clinical variables, treatment duration, final response, need for surgery, recurrence, and documented adverse events were analyzed. Ten patients (43.5%) achieved complete or near-complete resolution of the lesion, 6 (26.1%) showed a partial response at the end of treatment or prior to surgery, 5 (21.7%) did not respond or exhibited progression, and 2 (8.7%) were still receiving treatment at data cutoff. Twelve patients completed treatment without surgery; at cutoff, 14 (60.9%) had not undergone surgery, including the 2 cases still under treatment. Nine patients (39.1%) required surgery. No recurrences were documented among patients with complete or near-complete resolution during available follow-up, and no adverse events attributable to treatment were recorded. Topical timolol 0.5% can be considered an initial conservative alternative in selected pediatric patients, especially when avoiding or deferring surgery or anesthesia is desired. Surgery remains a definitive option, offering immediate resolution and the possibility of histological confirmation. Prospective comparative studies are needed to define more precisely the role of timolol compared to surgical treatment.

PMID 42992436
阅读全文 →
PubMedIndian journal of pediatrics2026-11-05

Vision-Threatening Giant Hemifacial Infantile Hemangioma Successfully Treated with Oral Propranolol and Topical Timolol.

Sarkar Sumantra S, Bandyopadhyay Rakhi R, Raza Arsalan A

PMID 42986507
阅读全文 →
PubMedCureus2026-11-05

Clinical Spectrum of Thyroid Eye Disease in a Tertiary Referral Centre in Eastern India: A Case Series.

J Renukha R, Kesarwani Divya D, Saha Bhawesh C BC, Raj Amit A et al.

Thyroid eye disease (TED) is a chronic autoimmune inflammatory disorder characterized by a wide spectrum of clinical manifestations ranging from mild features such as eyelid retraction and periorbital edema to vision-threatening complications like compressive optic neuropathy. The purpose of this case series is to highlight the clinical challenges, therapeutic dilemmas, and management complexities encountered in patients with TED. This case series includes five patients diagnosed with thyroid-associated orbitopathy. Four of five patients presented with proptosis, four had restrictive extraocular myopathy, one presented with isolated upper eyelid retraction, and four had elevated intraocular pressure. Three patients required intravenous methylprednisolone therapy for active disease, whereas two were managed conservatively with ocular lubricants and topical antiglaucoma medications. Disease activity was assessed using the Clinical Activity Score (CAS). Intravenous methylprednisolone was administered in indicated cases if disease was found to be active, moderate to severe, and sight-threatening, as per the European Group on Graves' Orbitopathy (EUGOGO) regimen. Post-treatment, patients demonstrated improvement in visual acuity, reduction in proptosis, and decreased eyelid edema. However, residual ocular deviation and extraocular motility restriction persisted, with minimal improvement. All patients underwent regular three-monthly follow-up for monitoring and rehabilitation. We found that systemic corticosteroid therapy was effective in controlling inflammatory activity and improving vision. However, restrictive myopathy and strabismus showed limited reversibility, indicating progression to the fibrotic phase in some cases. Thus, this case series underscores the chronic and potentially progressive nature of TED and highlights the need for a multidisciplinary, individualized treatment approach. Early recognition and timely intervention are critical in preventing irreversible vision loss. The persistence of functional and cosmetic sequelae necessitates long-term follow-up and, in many cases, staged reconstructive surgeries, thereby contributing to the overall social and psychological burden of the disease.

PMID 42985331
阅读全文 →

注册免费账户还可查看另外 7517 篇文献

免费注册查看全部文献 →

了解更多timolol